Conclusions
The SAPIEN 3 THV system was associated with low rates of 30-day mortality and major/disabling stroke as well as low rates of moderate or severe paravalvular regurgitation.
Trial Registration ClinicalTrials.gov #NCT01314313.
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Background
Based on randomized trials using the first-generation devices, transcatheter aortic valve replacement (TAVR) has been found superior to medical treatment in inoperable patients with aortic stenosis (AS) and at least equivalent to surgical aortic valve replacement (SAVR) in high-risk (HR) surgical candidates. 1 -6 Although SAVR remains the current standard of care in patients not considered high surgical risk, 7 emerging evidence suggests that equivalent outcomes may be achievable with TAVR in appropriately selected lower risk patients. 8, 9 Currently, there is a paucity of prospective data evaluating outcomes with TAVR in lower risk patients with the latest generation TAVR systems.
Reducing complications is imperative if TAVR is to be applied to intermediate -risk (IR) patients. Although operator experience, patient selection, and pre-procedural imaging are important in improving outcomes with TAVR, 10 -12 many complications of TAVR may relate directly to device technology. Consequently, the development of the next-generation devices is critical, especially in evaluating the use of TAVR in lower risk populations, wherein excellent clinical outcomes after SAVR are expected. We report early outcomes of a large, multicentre registry of inoperable, HR and IR patients undergoing TAVR with the newgeneration SAPIEN 3 transcatheter heart valve (THV).
Methods
Study design and patient selection
The Placement of Aortic Transcatheter Valves (PARTNER) II SAPIEN 3 trial was a prospective, multicentre study which enrolled patients with symptomatic (New York Heart Association functional class II or greater), severe AS who were either inoperable/HR or at IR of operative mortality with SAVR. Severe AS was defined as an aortic valve area (AVA) ≤0.8 cm 2 or indexed AVA ,0.5 cm 2 /m 2 and a mean gradient .40 mmHg or peak velocity .4 m/s. While the study definition of severe AS differs somewhat from that published in the most recent AHA/ACC and ESC guidelines, both guidelines specifically note that an AVA of 0.8 cm 2 correlates better with a maximum velocity of 4 m/s and mean gradient of .40 mmHg, when compared with a cut-off of 1 cm 2 . This has been well described in the work of Minners et al., 13 and supports the use of 0.8 cm 2 as a more consistent and haemodynamically relevant definition. Furthermore, this stricter definition is consistent with previously published major randomized studies. Key exclusion criteria were a congenitally bicuspid aortic valve, severe aortic regurgitation, a prior prosthetic valve in any position, left ventricular ejection fraction ,20%, stroke or transient ischaemic attack within 6 months, myocardial infarction within 1 month, upper gastrointestinal bleeding within 3 months, severe renal insufficiency (creatinine .3.0 mg/dL or dialysis dependent), and estimated life expectancy ,2 years. Patients with left main or multivessel coronary disease with Syntax score ≥32 were excluded. Patients with less severe but untreated significant coronary disease could be enrolled if a treatment plan for the coronary disease was agreed upon prior to enrolment. The complete list of inclusion and exclusion criteria is shown in Supplementary material online, Appendix.
Procedure
The Edwards SAPIEN 3 balloon-expandable THV consists of bovine pericardial leaflets sutured to a cobalt chromium frame ( Figure 1 ). An important component is a polyethylene terephthalate skirt that covers the lower portion of the frame, designed specifically to reduce paravalvular leak (PVL). The THV system is delivered through expandable 14-(20, 23, and 26 mm THV) or 16-Fr (29 mm THV) transfemoral (TF) delivery sheaths which expand to accommodate the device. The SAPIEN 3 THV can also be delivered via direct transaortic (TAo) or transapical (TA) routes. Procedures were performed via TF, TA, or TAo access, depending on pre-procedural vascular assessment. Patients were required to have an aortic annular area between 273 and 680 mm 2 , appropriate for treatment with a 20, 23, 26, or 29 mm SAPIEN 3 THV. Pre-procedural sizing was performed on the basis of systolic measurements of annular area from MDCT or three-dimensional TEE. During the course of the study, recommendations for sizing and valve positioning were changed whereby less oversizing (5-10% by annular area) and a higher deployment position was recommended. Following the procedure, treatment with aspirin and clopidogrel was recommended for 6 months. In the case of pre-existing oral anticoagulation therapy, either aspirin or clopidogrel could be discontinued at the discretion of the treating physician.
Oversight and data management
The trial was designed collaboratively by the sponsor (Edward Lifesciences, Irvine, CA, USA) and members of the executive steering Early clinical and echocardiographic outcomes with SAPIEN 3 THV committee. The sponsor funded the study, participated in the selection and management of sites, and monitored the data. The first author and co-principal investigators had unrestricted access to the data after the database was locked, prepared all drafts of the manuscript, and made the final decision to submit the manuscript. Data analysis was performed by independent statisticians at the Cardiovascular Research Foundation. The sponsor had no role in data analysis, drafting of the manuscript, or in the decision to publish.
Clinical assessments were performed at baseline and at 30 days, and included formal examination by a neurologist. Serial echocardiographic follow-up was performed immediately following implant (intra-procedural), within 24 h of hospital discharge, and at 30 days. A consortium of echocardiography core laboratories analysed all echocardiography independently. Clinical events were independently adjudicated by a clinical events committee and a data and safety monitoring board reviewed all adverse events.
Clinical outcomes
Stroke is reported according to modified VARC-2 definitions utilizing either a 30-or 90-day modified Rankin score to allow comparability with the surgical arm of the PARTNER IIA study. All other relevant clinical outcomes are reported according to VARC-2 endpoint definitions. Pre-procedure echocardiography assessments were compared with 30-day studies, with particular attention to aortic valve haemodynamics and PVL. If the 30-day study was not available, the pre-discharge study was analysed.
Statistical analysis
An as-treated analysis was performed which included all patients entering the procedure room for the TAVR. Echocardiographic analyses utilize the valve implant population (i.e. those who actually received the valve). Categorical variables were summarized as percentages while continuous variables were reported as mean + standard deviation. Time-to-event variables are presented as Kaplan-Meier estimates, using all available follow-up. Statistical comparisons between baseline and 30-day values were conducted with the use of paired t-tests or McNemar's test, as appropriate.
Results
Between October 2013 and February 2014, 583 inoperable/HR patients were enrolled at 29 implanting sites and between February 2014 and December 2014, 1078 IR patients were enrolled at 51 sites in the USA and Canada. One HR patient died before entering the procedure room.
Patient characteristics
The mean age of HR patients was 82.7 + 8.1 years, 58.0% were male, and the mean STS score was 8.7 + 3.7%. Frailty criteria were met by 30.9% of the HR patients. In this cohort, 64.7% were characterized as HR, the remainder as inoperable. The mean age of IR patients was 81.9 + 6.6 years, 61.8% were male, and the mean STS score was 5.3 + 1.3%. Of the IR patients, 8.9% had an STS score ,4%. Other baseline characteristics of both cohorts are shown in Table 1 .
Procedural factors
Transfemoral access was used in 84.2% of HR patients and 88.3% of IR patients. The distribution of THV sizes was 3.2% (20 mm), 32.9% (23 mm), 42.1% (26 mm), and 21.7% (29 mm). In the combined population (n ¼ 1661), monitored anaesthesia care was used in 257 (15.5%) and percutaneous closure was used in 1329 (80.3%). Overall, post-dilatation was performed in 208 (12.5%), valve embolization occurred in 2 (0.1%), annular rupture in 2 (0.1%), and more than one THV was required in 9 (0.5%) patients. Six patients (one HR patient and five IR patients) required conversion to open surgery, for valve embolization (two patients), annular rupture (two patients), left atrial appendage thrombus (one patient), and a low-lying right coronary artery (one patient). Procedural mortality was 1.0% (six patients) in HR and 0.5% (five patients) in IR cohorts. The median length of hospital stay was 3 days (interquartile range, IQR 2-6 days) for HR patients and 3 days (IQR 2 -4 days) for IR patients. Other procedural characteristics are shown in Table 2 . Repeat hospitalization occurred by 30 days in 8.0% of HR patients and 4.6% of IR patients. The rate of all strokes at 30 days was 1.4% (HR) and 2.7% (IR). The rate of major/disabling stroke (modified Rankin score ≥2 at 30 days) was 0.9% (HR) and 1.0% (IR). At Figure 1 The SAPIEN 3 transcatheter heart valve. The SAPIEN 3 is a balloon-expandable transcatheter heart valve that consists of bovine pericardial leaflets sutured to a cobalt chromium frame with a polyethylene terephthalate skirt covering the inflow potion of the frame (A). The valve is available in 20, 23, 26, and 29 mm sizes and is compatible with a 14-or 16-Fr transfemoral delivery system (B). The valve is deployed in an intra-annular position via balloon inflation (C and D).
30-day clinical outcomes
30 days, major bleeding had occurred in 14.0% (HR) and 10.6% (IR) and major vascular complications in 5.1% (HR) and 6.1% (IR). The rate of new permanent pacemaker was 13.3% in HR patients and 10.1% in IR patients. Outcomes based on access route for HR and IR cohorts are listed in Tables 4 and 5 .
At baseline, the distribution of symptoms by NYHA functional class for the overall cohort was 0.0% (class I), 21.3% (II), 60.6% (III), and 18.1% (IV). At 30 days, functional class status was 52.5% (class I), 38.8% (II), 7.6% (III), and 1.1% (IV). Patient symptoms improved from baseline to 30 days in both cohorts ( Figure 2) . From baseline to 30 days, mean 6 min walk test (6MWT) increased from 138.2 to 176.7 feet in HR patients (P , 0.0001) and from 197.0 to 231.3 feet in IR patients (P , 0.0001). Paired quality-of-life assessments at the same time points showed increases in mean overall Kansas City Cardiomyopathy Questionnaire score from 47.8 to 67.8 in HR patients (P , 0.0001) and from 54.7 to 74.0 in IR patients (P , 0.0001).
30-day echocardiography outcomes
There were no significant differences in the baseline echocardiographic findings when HR and IR cohorts were compared. Thirtyday (or pre-discharge) echocardiographic evaluation was performed in 1597/1661 (96.1%) of patients. The pooled baseline and 30-day echocardiographic outcomes of both HR and IR cohorts are shown in Table 6 . Overall, the mean AVA increased from 0.69 + 0.17 to 1.67 + 0.38 cm 2 (P , 0.0001) from baseline to 30 days. All THV sizes showed an increase in AVA from baseline to 30 days with the most significant proportional increase in AVA seen in larger valve sizes ( Figure 3A , P , 0.0001 for trend). The overall mean gradient decreased from 45. The logistic EuroSCORE II (European System for Cardiac Operative Risk Evaluation) estimates the risk of operative mortality following cardiac surgery and ranges from 0 to 100%, with higher scores indicating higher predicted risk of mortality.
11.4 + 4.8 mmHg at 30 days, with a similar proportional decrease in gradient seen when the overall cohort was stratified by THV size (P , 0.0001 for trend, Figure 3B ). At 30 days, 55.9% of patients had no/trace PVL, 40.7% mild, 3.4% moderate, and no patients had severe PVL. No patients had more than mild transvalvular aortic regurgitation; 1.4% had mild, 98.6% had none/trace.
Discussion
Compared with previous SAPIEN THV clinical trials, the results of this study show that treatment of HR/inoperable and IR AS patients with the new SAPIEN 3 THV is associated with the following: (i) low rates of 30-day mortality, stroke, and repeat hospitalization; (ii) significant improvements in symptoms, quality of life, and functional status; (iii) low rates of procedural complications including aortic/annulus rupture, coronary occlusion, valve embolization, or valve-in-valve implants; (iv) low rates of significant aortic regurgitation; (v) higher than previously observed rate of new permanent pacemakers; (vi) shorter duration length of hospital stay. The 30-day mortality reported in this study represents the lowest of any large TAVR registry and is a significant evolution in the field of TAVR. 14, 15 Over the last 5 years, 30-day mortality has decreased significantly from 5.0% in early studies with the original SAPIEN THV to 1 -2% in the current study with the new S3 THV. 1 Although the STS score for the HR cohort in this study was lower than that in the initial PARTNER I HR cohort, all patients were deemed to be HR due to the presence of factors not captured in the STS score, such as frailty. The apparent reductions in strokes, major vascular complications, life-threatening bleeding, and other acute procedural complications (e.g. annular rupture, coronary occlusion, and valve embolization), which contributed to early mortality in previous TAVR studies, are likely associated with the reduced mortality seen in this trial. Several other factors are likely to have contributed to these excellent results, including but not limited to: operator experience, improved patient selection, and the systematic use of MDCT for vascular access and annulus sizing. In addition, iterative improvements in the THV, as well as the delivery catheter, have also played an important role. The very low bleeding and vascular complication rates are related to a large degree to the SAPIEN 3 THV expandable sheath with internal dimensions of 14-or 16-Fr. Furthermore, diminishing sheath size also expanded the population eligible for TF access. In this study, TF access was utilized in 87% of cases, the highest rate of TF access in a major valve trial to date. Transfemoral access allows faster recovery and shorter hospital stay than non-TF access; one recent analysis demonstrated the mortality benefit of TF access in a propensity-matched cohort. 16 when compared with both SAVR and non-TF TAVR. 17 Interestingly, no difference in mortality was observed between non-TF and TF groups in the IR cohort despite greater co-morbidity in non-TF patients. Thus, in lower surgical risk patients with less co-morbidity, non-TF access may be better tolerated, with lower early mortality and complications. The low rate of stroke in this study deserves special attention. In prior TAVR studies, strokes have been a concern; all strokes or TIA at 30 days in PARTNER I were 6.7% for the inoperable cohort 1 and 5.5% for HR patients. 5 The neurologic event rates in the current study are the lowest reported in a large study with clinical events committee-adjudication. At 30 days, the rate of all stroke or TIA was 2.1% in HR patients and 3.1% in IR patients while disabling stroke (which was not a metric reported in studies of previous generation SAPIEN valves) was observed in only 0.9% of the HR patients and 0.7% of the IR patients. These results are striking when one considers that all patients in the current trial underwent evaluation by a neurologist at baseline and at 30-day follow-up. Previous studies that did not mandate formal neurological examination have likely underestimated the incidence of stroke. A recent study showed that with careful neurologic assessment, stroke after SAVR was much higher (17%) than previously reported. 18 This very low stroke rate could reflect many patient-or procedure-related factors, but could Deaths from unknown cause were assumed to be from cardiovascular causes.
c Major/disabling stroke was defined as modified Rankin score ≥2.
Early clinical and echocardiographic outcomes with SAPIEN 3 THV also relate to the lower crossing profile of the Sapien 3 system as well as greater active flexion by the delivery catheter resulting in less aortic arch injury. Moreover, previous studies of earlier SAPIEN generations have shown an association with post-dilatation and procedural strokes. 19 The effectiveness of the sealing cuff of the SAPIEN 3 THV in reducing PVL reduced the need for post-dilatation (performed in 12.5% of cases in this study), which, in turn could reduce the likelihood of stroke. Paravalvular leak remains an important consideration when comparing TAVR with SAVR; moderate -severe PVL at 30 days were 12.2 and 10% in the PARTNER IA and US CoreValve Pivotal Study TAVR cohorts, respectively. 4, 5 Even mild PVL was associated with increased mortality in earlier PARTNER analyses, 20 so modifications to prevent PVL have been a prominent focus in the development of the next-generation TAVR devices. The very low 30-day rate of moderate or severe PVL (3.4%) observed in this study is attributable partly to the systematic use of 3D imaging for correct THV size selection, but more likely reflects the effectiveness of the fabric skirt surrounding the inflow portion of the stent frame. These rates of PVL are in line with other next-generation devices that shown similarly low rates of moderate or greater PVL. 21, 22 These other studies, however, have shown higher rates of none -trace PVL, the clinical significance of which remains unknown. We also observed a slightly higher rate of new pacemakers in this study (13.0% for HR, 10.1% for IR), compared with the PARTNER I experience with the original SAPIEN THV (8.8%). 23 The reasons for a higher rate of new pacemakers are likely multifactorial. The SA-PIEN 3 THV has a longer stent frame than previous generation devices and there is increased foreshortening of the frame. Depending on the exact implantation characteristics (including depth and degree of oversizing), the final position of the valve may be lower in the LV outflow tract, leading to an increased risk of injury to the conduction system. When this trial started, guidance regarding valve positioning as well as oversizing was limited, leading to a lower position of the inflow portion of the SAPIEN 3 valve. During the course of the study, both positioning recommendations and sizing algorithms changed (MDCT sizing was mandated and less oversizing was recommended) which resulted in a higher position and greater foreshortening of the frame. This is potentially the reason for the lower incidence of pacemakers in the IR cohort, which enrolled after the HR cohort. A recent analysis of 101 IR patients from Europe demonstrated very low rates of new pacemakers (4%) after SA-PIEN 3 implantation utilizing the recent procedural guidance. 24 Careful further analyses of the predictors of new pacemaker requirements after SAPIEN 3 will be important especially as TAVR moves into the IR cohort. Finally, this is the largest series of IR TAVR patients reported thus far. As in the HR patients, the rates of major adverse events were remarkably low at 30 days (mortality 1.1%, disabling stroke 0.7%), although no direct comparisons with surgically treated patients are possible. In the future, after data from the PARTNER 2A randomized trial in IR patients are available, comparisons between this SAPIEN 3 registry and the randomized surgical arm would be appropriate and are planned. Nonetheless, the rates of mortality and stroke in the current study appear to be much lower than previously reported in large series of IR patients undergoing SAVR. 7 These results suggest that TAVR early mortality may be at least comparable with SAVR in IR patients and are consistent with the recently published NOTION trial, which randomized all-comers to TAVR or SAVR. Patients with a mean STS of 2.9% (TAVR) and 3.1% (SAVR) showed similar rates of adverse events at 1 year with TAVR vs. SAVR (13.1% vs. 16.3%, P ¼ 0.43 for the composite endpoint of death, stroke, and myocardial infarction). 8 NOTION trial outcomes were consistent with a recent propensity-matched analyses in which TAVR and SAVR appeared to have similar results in IR patients.
9,25
The very low rates of significant PVL and the excellent haemodynamic results with SAPIEN 3 in the IR cohort are important if TAVR is to be applied to lower risk populations. Most assuredly, longer follow-up is required to assess valve durability, but if the low rates of adverse events are sustained, TAVR could be a viable alternative to SAVR in the management of IR patients with AS. This study has a number of limitations. It is a registry with no randomized comparator arm. Also this study did not enrol HR patients consecutively and therefore may be confounded by selection bias. In particular, certain HR groups, such as patients on haemodialysis, were excluded. In addition, this study is confined to 30-day events, so further longer-term follow-up is required if these encouraging early results are to prove meaningful. Finally, this study was conducted during the earliest phases of introduction of the SAPIEN 3 THV, at which time optimal recommendations for valve sizing and THV positioning were in a state of evolution.
In summary, treatment of inoperable/HR AS patients with the SAPIEN 3 THV is associated with extremely low rates of mortality, major complications, and paravalvular leak at 30 days. Based upon these data and other recent literature, TAVR should be considered a Class I indication in HR patients. In IR patients, these data are encouraging and with presentation of longer-term follow-up within the next year, TAVR with the SAPIEN 3 valve may become an alternative to surgery in many elderly IR patients as well. Longer-term follow-up and future studies in even lower risk patients will eventually determine the role of TAVR and SAVR in the treatment algorithm of all patients with severe AS.
